June 20, 2014
A biosimilar of Mitsubishi Tanabe Pharma Corporation’s (MTPC) fully human anti-TNFα monoclonal antibody Remicade (infliximab), a treatment for rheumatoid arthritis and a number of other diseases, is expected to receive approval and be launched by Nippon Kayaku later this fiscal...read more